<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460222</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-26</org_study_id>
    <nct_id>NCT04460222</nct_id>
  </id_info>
  <brief_title>Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial</brief_title>
  <official_title>Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood products are commonly used before invasive procedures in patients with end-stage liver&#xD;
      diseases despite cirrhosis being a thrombophilic state. Traditional coagulation tests [namely&#xD;
      International Normalised Ratio (INR) and Platelets count] are known to be unreliable in&#xD;
      predicting bleeding risk before invasive procedures and in representing the real coagulation&#xD;
      status of cirrhotic patients. Notwithstanding they are still used to guide blood products&#xD;
      administration before invasive procedures. Rotational Thromboelastometry ( ROTEM) has been&#xD;
      shown to be effective in detecting signs of hypo-hypercoagulability possibly being an&#xD;
      alternative method to guide blood products transfusion. The aim of this randomized controlled&#xD;
      study is to evaluate the efficacy of ROTEM as a guide for blood products transfusion in&#xD;
      cirrhotic children undergoing invasive procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with cirrhosis listed for invasive procedures and with deranged INR between 1.5-2,5&#xD;
      and/or deranged platelet count between 20,000/mm3-50,000/mm3 will be included in the study&#xD;
      and will be block randomized into two groups. To prevent bleeding during the procedure, one&#xD;
      group will receive prophylactic transfusion of either fresh frozen plasma (FFP),Platelet or&#xD;
      Cryoprecipitate based on the values of INR, platelet and fibrinogen.The second group will&#xD;
      undergo ROTEM based correction.&#xD;
&#xD;
      Following correction, the procedure will be done in both the groups. Patients randomized in&#xD;
      the ROTEM group will undergo repeat ROTEM and INR, Platelet, Fibrinogen testing (depending on&#xD;
      the component transfused), post the procedure, to look at the correction achieved. Similarly,&#xD;
      patients randomized in the conventional group will undergo repeat INR, Platelet, fibrinogen&#xD;
      testing depending on the component transfused.&#xD;
&#xD;
      Patients will be followed for 24 hours indoors for any evidence of bleeding or transfusion&#xD;
      reaction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison in the amount of blood products transfused between the groups</measure>
    <time_frame>24 hours</time_frame>
    <description>To compare the amount of total component transfused (ml/kg) in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison in the amount of FFP transfused between the groups</measure>
    <time_frame>24 hours</time_frame>
    <description>To compare the amount of FFP (ml/kg) transfused in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison in the amount of Platelet transfused between the groups</measure>
    <time_frame>24 hours</time_frame>
    <description>To compare the amount of Platelet transfused in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison in the amount of Cryoprecipitate transfused between the groups</measure>
    <time_frame>24 hours</time_frame>
    <description>To compare the amount of Cryoprecipitate transfused in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure bleeding</measure>
    <time_frame>24 hours</time_frame>
    <description>Comparison of the number of patients having bleeding episodes after procedure between the study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion related side effects</measure>
    <time_frame>5 days</time_frame>
    <description>- To compare the rate of transfusion reactions in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between blood products costs between groups</measure>
    <time_frame>24 hours</time_frame>
    <description>To compare the cost of transfusion components incurred in Rotational Thromboelastometry guided therapy versus Conventional therapy for invasive procedures in children with cirrhosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Rotational Thromboelastometry (ROTEM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To prevent bleeding during invasive procedure, cirrhotic children in the ROTEM group will receive prophylactic transfusion based on the following protocol:- EXTEM CT &gt; 80 sec - FFP will be transfused at 15 ml/kg MCF &lt; 35 mm- Platelet will be transfused at 10 ml/kg FIBTEM MCF &lt; 7 mm- Cryoprecipitate will be transfused at 5 ml/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To prevent bleeding during the procedure, cirrhotic children in the conventional group will receive prophylactic transfusion if either FFP, Platelet or Cryoprecipitate is deranged based on the following protocol&#xD;
If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg&#xD;
If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg&#xD;
If Fibrinogen &lt; 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure</intervention_name>
    <description>Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if&#xD;
EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg&#xD;
FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg</description>
    <arm_group_label>Rotational Thromboelastometry (ROTEM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional transfusion methods to guide blood product transfusion pre invasive procedure</intervention_name>
    <description>Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen &lt; 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg</description>
    <arm_group_label>Conventional Transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children less than 18 years of age with histologic or image proven liver cirrhosis of&#xD;
             any etiology with INR ≥ 1.5- ≤ 2.5 and/or Platelet count 20,000/mm3- 50,000/mm3 and&#xD;
             who are listed for the following invasive procedures : Low risk of bleeding&#xD;
&#xD;
               1. Central venous cannulation&#xD;
&#xD;
               2. Haemodialysis catheter&#xD;
&#xD;
               3. Ascitic or Pleural tapping&#xD;
&#xD;
               4. Endoscopic variceal ligation (EVL)&#xD;
&#xD;
               5. Endoscopic sclerotherapy (EST)&#xD;
&#xD;
                  High risk of bleeding&#xD;
&#xD;
               6. TIPPS&#xD;
&#xD;
               7. Endoscopic retrograde cholangiopancreatography (ERCP) with sphicterotomy&#xD;
&#xD;
               8. Percutaneous drain (PCD) Insertion&#xD;
&#xD;
               9. Biopsies other than liver biopsy&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Anti platelet or anti coagulant therapy in the previous 7 days&#xD;
&#xD;
          -  Patients with clinical evidence of Disseminated intravascular coagulation (DIC) and/or&#xD;
             active bleeding&#xD;
&#xD;
          -  Hemodialysis in the past 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seema B Alam, MD</last_name>
    <phone>9540951008</phone>
    <email>seema_alam@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arjun Maria, DNB</last_name>
    <phone>9871881858</phone>
    <email>arjunmaria0@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Institute of Liver and B Sciences</last_name>
      <phone>9540951008</phone>
      <email>seema_alam@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>February 14, 2021</last_update_submitted>
  <last_update_submitted_qc>February 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ROTEM</keyword>
  <keyword>Transfusion</keyword>
  <keyword>Pre invasive procedure</keyword>
  <keyword>Coagulation disorders</keyword>
  <keyword>Pediatric liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

